Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

This review discusses the impact of medical and surgical treatments for LUTS/BPH on ejaculatory function, highlighting that most treatments negatively affect it, except for some minimally invasive surgical therapies and specific medical therapies.

This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.

This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.

This study found that treatment with imipramine and pseudoephedrine can effectively restore antegrade ejaculation in diabetic patients suffering from retrograde ejaculation, offering potential fertility solutions through natural or assisted reproductive methods.

This study found that the MTCK, a masturbation aid, significantly improved intravaginal ejaculation latency time and some related sexual function scores in men with premature ejaculation after 8 weeks of use.

This review discusses the classification and treatment of ejaculatory dysfunction, outlining both pharmacotherapy and behavioral therapy as primary interventions, but does not present new clinical findings.

This review discusses the pathophysiology of delayed ejaculation, highlighting the role of various biogenic and psychogenic factors, but reports no new clinical findings.

This article reviews the management of excessive pre-ejaculate, highlighting case reports where 5-α-reductase inhibitors, such as finasteride and dutasteride, led to symptom resolution in patients reporting distress due to this condition.

This study found that among ten identified medications associated with ejaculatory disorders, Paroxetine and Tamsulosin were mainly linked to delayed and retrograde ejaculation, while Finasteride and Sildenafil were most associated with painful ejaculation and ejaculation failure according to reports from FDA-FAERS and Eudra-Vigilance databases.

In this retrospective study at Toyama University Hospital, amoxapine was reported to significantly improve semen volume, sperm concentration, and total sperm count in 17 men with ejaculatory disorders, with no observed side effects over an average of 13 months of therapy.

This study found that SDG did not significantly affect prostate weight in rats with BPH, but it may reduce serum PAP activity and alter prostate tissue changes induced by Testosterone Propionate.

This case study observed that in four middle-aged men with ejaculation disorders, therapy with human chorionic gonadotropin (hCG) alone or combined with recombinant follicle-stimulating hormone (rFSH) improved sexual desire, semen volume, and various other symptoms, although some experienced elevated estradiol levels and hair loss.

This study found that combining α 1A-blockers with Prozac was more effective for treating premature ejaculation than using Prozac alone.

This study concluded that daily treatment with 1 mg finasteride did not affect spermatogenesis or semen production in young men and had small, reversible effects on prostate volume and serum PSA.

This study found that men experiencing long-term symptoms after finasteride use for androgenetic alopecia frequently reported loss of penis sensitivity and anhedonia, among other effects, indicating potential post-finasteride syndrome.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This article reviews multiple entries on the Androlog blog regarding finasteride use, concluding that a 1-mg dose does not adversely affect spermatogenesis or pose a risk during conception or pregnancy.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.

This article reviews the impact of aging and related urologic conditions on male fertility, highlighting the effects of various treatments on sperm parameters and recommending pre-treatment counseling for fertility preservation. It reports no new clinical results.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This study found that steroid hormones influence the quality indicators of fresh and cryopreserved stallion sperm, with testosterone negatively correlated with motility and estradiol positively correlated with survival rate.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

This study found that adolescent men in Ireland are more likely to prefer keeping a baby over abortion in a hypothetical unplanned pregnancy, influenced by their anticipated regret and perceived familial attitudes.

This review discusses the use of finasteride for treating androgenetic alopecia in men, noting its effectiveness in maintaining and regrowing hair on the scalp and top of the head.

This review discusses the role of dihydrotestosterone in benign prostatic hyperplasia and reports no new results; the authors highlight 5alpha-reductase inhibitors as a well-established treatment option.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

This review highlights that sexual dysfunction associated with 5-alpha-reductase inhibitors is recognized in clinical literature, with erectile dysfunction being the most common adverse effect, followed by ejaculatory dysfunction and decreased libido.